Louis Garguilo

ARTICLES BY LOUIS

  • It Could Be At Takeda Or P&G: The Three Pieces of Outsourcing
    It Could Be At Takeda Or P&G: The Three Pieces of Outsourcing

    Three pieces for working with contractors and external supply-chains are Communication, Transparency for Problem Resolution, and Benefit Sharing, says William A. (Al) Kentrup, VP Global Quality Compliance and Systems, Takeda Pharmaceutical Company, and former director of corporate quality at Procter and Gamble.

  • M&A Crucible in Contract Drug Development And Manufacturing
    M&A Crucible in Contract Drug Development And Manufacturing

    According to a new industry report, the major contract development and manufacturing organizations only command a 2-4% market share each. Nonetheless, there is substantial M&A activity in the sector, and it certainly feels like we’re on a cusp of major consolidation. Let’s look at the evidence and momentum.

  • Adversity On The Path to Global Drug Distribution
    Adversity On The Path to Global Drug Distribution

    Not all Outsourced Pharma readers will have had experiences as pronounced as Jennifer Dent’s. But her narrative can spur us to take a look at our own personal – and organizational – missions within the greater biotech and pharma realm, and point to another area where outsourcing drug development and manufacturing professionals can step up our global leadership.

  • High Potency Service Providers: The Contenders And Pretenders
    High Potency Service Providers: The Contenders And Pretenders

    Is your CMO as accomplished at handling high-potency (HP) compounds as you think? Perhaps you’d better learn to separate "the contenders from the pretenders.” Here’s how.

  • The “Isle Of Difference” In Contract Development And Manufacturing
    The “Isle Of Difference” In Contract Development And Manufacturing

    On the way to Life Science Leader magazine’s annual CMO Leadership Awards in Manhattan, we detoured to the “Isle of Difference.” This is a location where service providers devise sales and marketing strategies to entice circling customers to put down anchors with them, instead of at a competitor’s shores. 

  • At Novartis, It’s The Quality In Continuous Manufacturing
    At Novartis, It’s The Quality In Continuous Manufacturing

    The head of continuous manufacturing at Novartis has a different view from the director of the Novartis-MIT Center for Continuous Manufacturing, when it comes to the technology's top benefit. “For the first time in history,” says Markus Krumme, “the industry can operate such that there's a 100% quality verification.”

  • Outsourced Pharmaceutical Manufacturing Grows To $76 Billion
    Outsourced Pharmaceutical Manufacturing Grows To $76 Billion

    The outsourced manufacturing sector should continue its growth at a clip of 6.6% over the next five years, faster than the projected annual growth rate of the overall pharmaceutical industry (5.5%). That’s according to a new report from Results Healthcare, Pharma & Biotech 2017 Review of outsourced manufacturing.

  • Novartis And The Arrival Of The Continuous Manufacturing Facility
    Novartis And The Arrival Of The Continuous Manufacturing Facility

    The journey to implementation of the disruptive technology of continuous manufacturing began in 2005, according to Markus Krumme of Novartis, with a single question on a slide presented to Novartis development and manufacturing executives. “Why don’t we have facilities that can continuously produce materials?” then-CEO Daniel Vasella asked.

  • Three Experiences Power A Non-Profit’s Business Approach
    Three Experiences Power A Non-Profit’s Business Approach

    Jennifer Dent is all business. At a nonprofit organization. She thinks that's exactly how it’s supposed to be. She also shares the enthusiasm of a humanitarian on a mission. Reviewing three experiences in the career of Dent, president of BIO Ventures for Global Health (BVGH), one might think none of this should be the case.

  • Vaccine Development Skating On Start-Ups
    Vaccine Development Skating On Start-Ups

    Ernst Soethout formed Virtuvax last year to take advantage of and further propel vaccine development trends, the most important being: “Big Pharma is ‘outsourcing’ R&D.” That in turn is driving the formation of virtual vaccine companies.”

Louis Garguilo

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.